Results 201 to 210 of about 49,910 (293)

A Catalytic Osmium Redox Couple Collapses Cancer Redox Balance

open access: yesAdvanced Science, EarlyView.
A stable Os(III)/Os(IV) redox couple is developed to disrupt the tumor cell redox balance by concurrently catalyzing ROS generation and GSH depletion. Osmium‐treated cells exhibit multiple cell death pathways, including apoptosis, ferroptosis, and immunogenic cell death.
Wan‐Qiong Huang   +9 more
wiley   +1 more source

sgRNA amount is a limiting factor in adenine base editing using RNA LNPs. [PDF]

open access: yesMol Ther Nucleic Acids
Birkenshaw A   +10 more
europepmc   +1 more source

PIEZO1 is Required for Acute Myeloid Leukemia Progression and Leukemia Stem Cell Maintenance via HIF1A‐SLC7A11 Axis‐Mediated Ferroptosis Defense

open access: yesAdvanced Science, EarlyView.
This study identifies the mechanosensor PIEZO1 as a key factor in promoting acute myeloid leukemia progression and uncovers a ferroptosis defense system mediated by PIEZO1‐HIF1A‐SLC7A11 axis that is essential for leukemia stem cell maintenance. This ferroptotic defense system may represent a unique vulnerability for leukemia stem cells, providing a ...
Tiantian Zhang   +10 more
wiley   +1 more source

PANX2 Suppresses Lung Adenocarcinoma Progression by Inducing Disulfidptosis and Enhancing Antitumor Immunity

open access: yesAdvanced Science, EarlyView.
ABSTRACT Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality with limited therapeutic options. Disulfidptosis, a novel cell death modality driven by disulfide stress, represents a promising target, yet its regulation in LUAD is poorly defined. Here, we identify Pannexin 2 (PANX2) as a tumor suppressor in LUAD.
Yi Chen   +7 more
wiley   +1 more source

Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

open access: yesAdvanced Science, EarlyView.
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy